Symbols

SOPH

Sophia Genetics·NASDAQ

--(--)

SOPH fundamentals

SOPH Q4 2025 Earnings

Sophia Genetics (SOPH) released its earnings on Mar 3, 2026: revenue was 21.71M (YoY +22.41%), beat estimates; EPS was -0.28 (YoY -21.74%), missed estimates.

Revenue / YoY

21.71M

+22.41%

EPS / YoY

-0.28

-21.74%

Report date

Mar 3, 2026

SOPH Earnings Call Summary for Q4,2025

Record 2025 growth: 124 new customers, 1 petabyte data processed, 74.2% adjusted gross margin.
Digital Twins launch: Multi-model AI solution for oncology, with lung cancer adoption.
2026 guidance: $92-94M revenue (+20-22%), EBITDA loss reduction to $29-32M.
Strategic wins: 2 U.S. health systems, MSK-ACCESS adoption, AstraZeneca renewal.
Risks: FX volatility, $1.8M litigation costs, biopharma pipeline uncertainty.

Earnings

EPS

Revenue

Revenue & Expenses

SOPH has released its 2025 Q4 earnings report, with revenue of 21.71M, reflecting a YoY change of 22.41%, and net profit of -19.18M, showing a YoY change of -26.53%. The Sankey diagram below clearly presents SOPH's revenue sources and cost distribution.

Key Indicators

Sophia Genetics (SOPH) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Sophia Genetics (SOPH)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Sophia Genetics (SOPH)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Sophia Genetics (SOPH)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown